Why the study?
Does synthetic ANF reduce blood pressure and alter kallikrein and cGMP levels in renovascular hypertensive rats?
Does synthetic ANF reduce blood pressure and alter kallikrein and cGMP levels in renovascular hypertensive rats?
Synthetic ANF induces significant hypotension and diuresis in renovascular hypertensive rats, potentially mediated by vasodilation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for synthetic ANF in renovascular hypertension; prospective human studies needed before clinical adoption.
The intravenous injection of an ED50 natriuretic dose (1 microgram) of synthetic ANF decreases blood pressure by 61 +/- 6 mmHg in 2-K, 1-C, and of 45 +/- 6 mmHg in 1-K, 1-C hypertensive rats, which was positively correlated with its initial level only in the 2-K, 1-C group. The hypotensive response lasted longer in the latter (greater than 40 min) than in normotensive sham-operated rats. No difference in duration was seen between 1-K, 1-C hypertensive and its uninephrectomized normotensive controls. The diuretic response to ANF was higher in 2-K, 1-C rats. No hematocrit changes were observed in any group. ANF induced a rise in urinary kallikrein in all groups but the 1-K, 1-C. Urinary kallikrein excretion was positively correlated with natriuresis in normotensive but not in hypertensive groups. ANF induced an increase in urinary cGMP excretion in all groups but the 1-K, 1-C, and an increase in plasma cGMP in the normotensive sham-operated animals. Our results suggest that the fall in blood pressure induced by synthetic ANF could be due to vasodilatation, a drop in cardiac output cannot, however, be eliminated. Whether the hypotensive effect of ANF is mediated by cGMP remains to be demonstrated.
No takes yet. Share an insight, caveat, or question.
García et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: